SGLT-2 inhibitors improve cardiac function in hypertrophic cardiomyopathy: a real-world propensity score-matched study
SGLT-2i administration was associated with improved left ventricular diastolic function and NYHA class in HCM patients without increasing risks of renal dysfunction or hypoglycemia, supporting its potential therapeutic value in this population.
Authors
- Fangchao Lv (ORCID: https://orcid.org/0000-0002-7719-9965)
- Lin Wang (ORCID: https://orcid.org/0000-0002-1420-7761)
- Xiaohong Xu (ORCID: https://orcid.org/0000-0002-3860-9845)
- Cong Ding
Institutions
- Westlake University (CN)
- Zhejiang Hospital (CN)
- Affiliated Hangzhou First People's Hospital, Westlake University, School of Medicine (CN)
Publication Details
- Journal
- Frontiers in Cardiovascular Medicine
- Published
- 2026-02-12
- DOI
- https://doi.org/10.3389/fcvm.2026.1742682
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Zhejiang Medical Association